EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

The impact of type 2 diabetes on sex-specific and stage-specific melanoma recurrence and mortality: a Danish cohort study, 2004–2024

Jens E Lyngstrand iD, Eeva-Liisa Røssell iD, Marie L Bønnelykke-Behrndtz, Tinne Laurberg

British Journal of Dermatology · 17.07.2026 · 195 (2) · 241-251

DOI: 10.1093/bjd/ljag097 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift British Journal of Dermatology, online erschienen am 15.03.2026. Verfasst von Jens E Lyngstrand und 3 weiteren Autor:innen. Beteiligte Einrichtung: Steno Diabetes Centre Aarhus, Aarhus University Hospital, Aarhus, Denmark. Hauptthemen laut MEDLINE: Melanoma, Diabetes Mellitus, Type 2, Skin Neoplasms, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Danish Cancer Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The incidence of both melanoma and type 2 diabetes (T2D) is increasing. Recent studies suggest that T2D is associated with a more advanced melanoma stage at diagnosis, but its impact on melanoma prognosis remains unclear.

Objectives

To examine the impact of T2D on sex-specific and stage-specific melanoma recurrence, melanoma-specific mortality and overall mortality.

Methods

This population-based cohort study included all patients diagnosed with melanoma in Denmark between 2004 and 2022, excluding those with prior cancer or type 1 diabetes. The impact of T2D on melanoma recurrence, melanoma-specific mortality and overall mortality was assessed by stage [American Joint Committee on Cancer stage I–II (localized), stage III (locoregional) and stage IV (metastatic)] and stratified by sex. Cumulative incidence proportions and risk differences (RDs) were estimated. Furthermore, regression analyses using competing-risk models to estimate adjusted hazard ratios (aHRs) were applied, adjusting for age, comorbidity, calendar year and stage at diagnosis. Patients were followed from the date of melanoma diagnosis until death, emigration or the end of the study period (31 December 2024).

Results

This study included 30,365 individuals diagnosed with melanoma; 14,343 were men (1195 with T2D), and 16,022 were women (816 with T2D), with higher event frequencies in men than women. Among men with localized melanoma, T2D was associated with higher 5-year risks of recurrence (15.0% vs. 8.3%, aHR 1.30, 95% confidence interval (CI) 1.08–1.56) and melanoma-specific mortality (8.5% vs. 4.2%, aHR 1.28, 95% CI 1.00–1.64). Among women with localized melanoma, the T2D-associated RDs were less pronounced, and no associations were observed after adjustment: recurrence aHR 1.04 (95% CI 0.78–1.38) and melanoma-specific mortality aHR 1.10 (95% CI 0.75–1.61). For both sexes with either locoregional or metastatic melanoma, T2D had no prognostic impact.

Conclusions

T2D was associated with poorer prognosis among men with localized melanoma, whereas no prognostic impact was observed among women or patients with more advanced disease. These findings indicate the need for closer monitoring of men with early-stage melanoma and T2D and for further studies to clarify underlying mechanisms and the potential benefits of optimized diabetes management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaDiabetes Mellitus, Type 2Skin NeoplasmsNeoplasm Recurrence, LocalHumansMaleDenmarkFemaleAgedMiddle AgedNeoplasm StagingCohort StudiesIncidenceSex FactorsAdultPrognosisAged, 80 and overRisk Factors

Autor:innen und Institutionen

  • Steno Diabetes Centre Aarhus, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Plastic and Breast Surgery, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Pathology, Aarhus University Hospital, Aarhus, Denmark.

ORCID-Profile: Jens E Lyngstrand, Eeva-Liisa Røssell

Förderung

  • the Danish Cancer Society

Zitieren

APA

Lyngstrand, J. E., Røssell, E. L., Bønnelykke-Behrndtz, M. L., & Laurberg, T. (2026). The impact of type 2 diabetes on sex-specific and stage-specific melanoma recurrence and mortality: a Danish cohort study, 2004–2024. British Journal of Dermatology, 195(2), 241-251. https://doi.org/10.1093/bjd/ljag097

Vancouver

Lyngstrand JE, Røssell EL, Bønnelykke-Behrndtz ML, Laurberg T. The impact of type 2 diabetes on sex-specific and stage-specific melanoma recurrence and mortality: a Danish cohort study, 2004–2024. British Journal of Dermatology. 2026;195(2):241-251. doi:10.1093/bjd/ljag097

BibTeX
@article{Lyngstrand2026,
  author = {Lyngstrand, Jens E and Røssell, Eeva-Liisa and Bønnelykke-Behrndtz, Marie L and Laurberg, Tinne},
  title = {The impact of type 2 diabetes on sex-specific and stage-specific melanoma recurrence and mortality: a Danish cohort study, 2004–2024},
  journal = {British Journal of Dermatology},
  year = {2026},
  volume = {195},
  number = {2},
  pages = {241--251},
  doi = {10.1093/bjd/ljag097}
}
Kostenlos starten →